Test ID: BADX
BCR/ABL1, Qualitative, Diagnostic Assay
‹ Back to Hematology index
Total RNA is extracted from the patientâ€™s blood or bone marrow at the time of diagnosis and mRNA is reverse transcribed into cDNA. The cDNA is then subjected to PCR using 4 separate multiplex reactions. A qualitative result, which will include the relative ratio of target translocation mRNA to control GUSB gene mRNA, will be given by LightCycler 96 software. Although this method employs a quantitative PCR platform, the results can be used to evaluate the relative expression levels of the translocation mRNA relative to control mRNA, thus providing an improved measure of RNA quality in the assay. Reporting of results will be qualitative; either BCR-ABL1 mRNA positive/detected (with transcript type) or negative/not detected. (Instrument manual LightCycler 96 Real-Time PCR System. Roche Applied Science. Indianapolis, IN 2013)
Monday through Friday; 2 p.m.
RNA: Up to 3 months